drugset / Trial / NCT03047057

Lidocaine Infusion in Radical Cystectomy

NCT03047057

Phase 2 Completed 57 enrolled Assiut University
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Radical cystectomy (RC) remains the gold standard for treatment of patients with muscle invasive bladder cancer, or recurrent high grade non-muscle invasive bladder cancer. Nowadays, enhanced recovery pathway is used to decrease morbidity and improve acute rehabilitation after RC. Postoperative ileus is the most frequent reason for prolonged hospital stay following cystectomy.

Timeline

Start
2017-03-03
Primary completion
2018-07-20
Completion
2018-07-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified 2 mg Intravenous

Indications